David Shaw’s Alto Neuroscience ANRO Stock Holding History

David Shaw’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-45,343	Closed	-$1.02M	–	5283
2026 Q1	$1.02M	Sell	45,343 -79,452	-64%	-$1.47M	﹤0.01%	3426
2025 Q4	$2.22M	Buy	+124,795	New	+$1.57M	﹤0.01%	2972

Other funds holding ANRO

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SSC

Spruce Street Capital New York $510M AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

David Shaw's ANRO Position: Q2 2026 in Review

David Shaw sold out of Alto Neuroscience (ANRO) in Q2 2026, closing a stake of 45,343 shares — an estimated $1.02M sold.

David Shaw first reported a position in ANRO in Q4 2025 and held it in 2 quarters. The position peaked at $2.22M in Q4 2025. 113 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

David Shaw reported no remaining Alto Neuroscience position as of Q2 2026 after selling out during the quarter.
David Shaw sold 45,343 Alto Neuroscience shares in Q2 2026, an estimated $1.02M.
David Shaw first reported a position in Alto Neuroscience in Q4 2025 and held it in 2 quarters.
David Shaw's Alto Neuroscience position peaked at $2.22M in Q4 2025.
113 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.